Impact of Adoption of Chemoradiotherapy on the Outcome of Cervical Cancer in Ontario: Results of a Population-Based Cohort Study

Pearcey, R.; Miao, Qun; Kong, Weidong; Zhang-Salomons, Jina; Mackillop, William J.

doi:10.1200/jco.2006.09.1926

Cited by 61 publications

(49 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies demonstrate that concurrent chemoradiotherapy is better than chemotherapy alone preoperatively (Eifel et al, 2004;Pearcey et al, 2007;Rose et al, 2007;Stehman et al, 2007), which is also implied in our study.…”

supporting

confidence: 79%

Values of Three Different Preoperative Regimens in Comprehensive Treatment For Young Patients with Stage Ib2 Cervical Cancer

Zhao¹,

Wang²,

Chen³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cervical cancer tends to occur at an early age. Treatment for cervical cancer includes surgery, chemotherapy, radiotherapy or their combination. The 2-year survival of early cervical cancer after surgery or chemoradiothearpy reaches over 80%. Stage Ib2 cervical cancer, however, is a high-risk early stage cervical cancer with easy recurrence and metastasis. Its 5-year survival is as low as about 50%. Thus how to increase survival and decreases mortality of stage Ib2 cervical cancer is a hot spot in genealogical cancer research. Materials and Methods General dataOne hundred and twelve young patients below 35 years with stage Ib2 cervical cancer were enrolled retrospectively in our hospital from January, 2003 to June, 2005. They ranged in age from 20 to 35 years with a median age of 32 years. The cases of cervical cancer were all confirmed as invasive cancer by our Department of Pathology, including (Group 1, n=38), the neoadjuvant chemotherapy (Group 2, n=49), and the intracavity brachytherapy group (Group 3, n=25). Radical hysterectomy was performed following these regimens. Chemotherapy and radiotherapy were given according to pelvic lymph node metastasis, deep cervical stromal invasion, intravascular cancer emboli, histological grading, vaginal stump and positive surgical margin. Results: The cancer disappearance and superficial muscle invasion rates were statistically significantly better in the concurrent chemoradiotherapy group than in the other two groups (P<0.01). No statistically significant difference was noted in the deep muscle invasion rate, surgical time and intraoperative blood loss among three groups, but significantly more postoperative complications occurred in the concurrent chemoradiotherapy group. The 2-year pelvic recurrence was statistically significantly lower in the concurrent chemoradiotherapy group compared to other two groups, while the 5-year survival was higher. Conclusion: Concurrent chemoradiotherapy is efficacious for young patients with stage Ib2 cervical cancer.

show abstract

supporting

confidence: 79%

Values of Three Different Preoperative Regimens in Comprehensive Treatment For Young Patients with Stage Ib2 Cervical Cancer

Zhao¹,

Wang²,

Chen³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Importantly, the implementation of chemoradiotherapy in practice has been associated with an estimated 5 to 8% increase in 3-year survival at the population level [47]; [49]. This is of similar in magnitude to the 7% absolute 5-year survival benefit seen in the most recent synthesis of the chemoradiotherapy trials [21].…”

Section: Discussionmentioning

confidence: 78%

“…Undoubtedly, the biggest advance has come from combining chemotherapy concomitantly with radiotherapy. The publication of five large trials, each showing a benefit associated with cisplatin-based chemoradiotherapy, prompted a rare NCI alert that has led to dramatic and widespread uptake of concomitant chemoradiotherapy in practice, as either definitive or adjuvant therapy [46]; [47]; [48]; [49].…”

Section: Discussionmentioning

confidence: 99%

“…Cisplatin is the most commonly used drug [46]; [48], usually administered weekly [48], as a single agent [48] [49], and this is supported by the evidence to date [16]; [17]; [21]. In addition, the use of chemoradiotherapy based on cisplatin combinations [49]; [49]; [46], non-platinum drugs, such as 5-FU, or non-platinum combinations [49] also seems reasonably evidencebased [21].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the use of chemoradiotherapy based on cisplatin combinations [49]; [49]; [46], non-platinum drugs, such as 5-FU, or non-platinum combinations [49] also seems reasonably evidencebased [21]. One randomised trial directly comparing cisplatin with 5FU-based chemoradiotherapy closed early after interim analyses showed higher rates of progression with 5-FU [50], but was no longer powered to detect a difference in progression-free or overall survival, and so is inconclusive in this regard.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Concomitant and Neoadjuvant Chemotherapy for Cervical Cancer

Tierney¹,

Vale²,

Symonds³

2008

Clinical Oncology

View full text Add to dashboard Cite

In the past, women with early stage cervical cancer have been treated with radical radiotherapy or radical surgery, and women with locally advanced disease with radical radiotherapy, each offering a good chance of cure. Numerous trials have investigated whether giving cytotoxic chemotherapy alongside radiotherapy or prior to local treatment could augment the established benefits of these therapies, and are reviewed here. There is a strong basis for the use of platinum-based chemoradiotherapy, the current standard of care, but little convincing evidence as to the therapeutic benefits of using concomitant hydroxyurea. Chemoradiotherapy based on other non-platinum agents may offer alternatives. The effect of chemoradiotherapy appears to vary according to the stage of disease, but all types of women benefit. Neoadjuvant chemotherapy prior to radiotherapy could jeopardise survival and should be avoided unless perhaps a 'quick', dose intense regimen is used. Neoadjuvant chemotherapy before surgery may be beneficial, but the approach will remain controversial until it is tested against platinum-based chemoradiotherapy. Future studies many include combinations of other cytotoxics such as topotecan with cisplatin-based concomitant chemoradiotherapy or the addition of agents targeted against specific receptors such as EGFR.

show abstract

Translating New Medical Therapies Into Societal Benefit

Booth¹,

Mackillop²

2008

JAMA

Self Cite

View full text Add to dashboard Cite

Impact of Adoption of Chemoradiotherapy on the Outcome of Cervical Cancer in Ontario: Results of a Population-Based Cohort Study

Abstract: The adoption of C-CRT was associated with a significant improvement in overall survival of cervical cancer at the population level. The magnitude of the benefit of C-CRT in the general population was consistent with the results of the relevant clinical trials.

Cited by 61 publications

References 34 publications

Values of Three Different Preoperative Regimens in Comprehensive Treatment For Young Patients with Stage Ib2 Cervical Cancer

Values of Three Different Preoperative Regimens in Comprehensive Treatment For Young Patients with Stage Ib2 Cervical Cancer

Concomitant and Neoadjuvant Chemotherapy for Cervical Cancer

Translating New Medical Therapies Into Societal Benefit

Contact Info

Product

Resources

About